GlassScriptPhysician profile
Kevin B Collen
NPI 1235153446
$1,463.50
in general payments reported to CMS, 2019-2025
20 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $106 · 2021: $259 · 2022: $204 · 2023: $228 · 2024: $343 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.71 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $237.83 | 2019-2025 | Spravato |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $197.06 | 2021-2024 | Ingrezza |
| Abbvie INC. | $121.73 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $107.95 | 2019-2024 | Rexulti |
| Alkermes, INC. | $101.21 | 2021-2025 | Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $84.91 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.45 | 2020-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $42.73 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.68 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $33.40 | 2021 | |
| Lundbeck LLC | $31.80 | 2022 | |
| Neos Therapeutics, LP | $29.89 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.32 | 2025 | Cobenfy |
| Eisai INC. | $28.72 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $24.56 | 2023 | Dyanavel Xr |
| Corium, LLC | $20.71 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $20.69 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $19.16 | 2023 | Auvelity |
| Allergan, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Collen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.